| |
Responded study questionnaires
|
p value
|
|---|
|
Yes
|
No
|
|---|
|
(n = 77)
|
(n = 15)
|
|---|
|
Gender (males)
|
55.8%
|
66.7%
|
0.44
|
|
Late onset (≥50 years)
|
39.0%
|
26.7%
|
0.37
|
|
TTR V30M mutation
|
98.7%
|
93.3%
|
0.19
|
|
Age at onset (years)
|
47.3 (24.1-66.0)
|
39.5 (22.1-65.5)
|
0.07
|
|
Age at LTx (years)
|
50.1 (29.6-69.2)
|
42.4 (25.2-67.9)
|
0.08
|
|
Disease duration at LTx (years)
|
3.3 (0.5-12.1)
|
3.1 (1.9-9.0)
|
0.61
|
|
T50 pre LTx (min)
|
118 (48–350)
|
122 (56–235)
|
0.81
|
|
Total GI symptom score pre LTx
|
7 (0–35)
|
5.5 (0–21)
|
0.39
|
|
mBMI pre LTx
|
993 (550–1447)
|
973 (796–1320)
|
0.67
|
|
Age at study start (years)
|
58.9 (35.1-75.6)
|
53.3 (41.7-75.5)
|
0.12
|
- Data shown are medians (min-max) and p < 0.05 was regarded as statistically significant. LTx: liver transplantation, mBMI: modified body mass index, n: number of subjects, T50: gastric emptying half-time, TTR: transthyretin.
